Vantictumab

Vantictumab /vænˈtɪktʊmæb/ is a human IgG2 monoclonal antibody designed for the treatment of cancer.[1]

Vantictumab
Monoclonal antibody
Type?
SourceHuman
TargetFrizzled receptor
Clinical data
Routes of
administration
IV
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6322H9722N1674O1988S46
Molar mass142461.81 g·mol−1

This drug was developed by OncoMed Pharmaceuticals Inc. in partnership with Bayer.[2] OncoMed was awarded a patent in 2016, which is set to expire in 2029.[3] In April 2017, Bayer terminated its option to license vantictumab.[4]

It inhibits wnt signalling by targeting the frizzled receptors on cancer cells.[5]

Phase I trials have been completed for pancreatic cancer, non-small cell lung cancer, and breast cancer. In 2016 results were reported from a phase 1b clinical trial for triple-negative breast cancer[5][6] and in 2020 for pancreatic cancer.[7]

References


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.